I followed the link from TFA: "The study that led to approval enrolled 111 patients at 22 hospitals; 101 of them received Yescarta. They had one of three disea

I followed the link from TFA: "The study that led to approval enrolled 111 patients at 22 hospitals; 101 of them received Yescarta. They had one of three diseases: diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma or transformed follicular lymphoma." The study that led to approval is unpublished.